PharmiWeb.com - Global Pharma News & Resources

Press Releases

Date Title Company
22-Apr-2026 Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS Businesswire
22-Apr-2026 Ono Pharma Announces Upcoming Presentations at the ASCO 2026 Annual Meeting Businesswire
22-Apr-2026 Synthekine Presents Updated Clinical and Translational Data Demonstrating Strong Activity for STK‑012 in First‑Line Non‑Squamous NSCLC in Oral Presentation at AACR 2026 Businesswire
22-Apr-2026 From IVF Science to Skin Longevity: AV Laboratories Translates Biotechnology into Breakthrough Skincare Businesswire
22-Apr-2026 Nanomerics Secures US Patent Extending MET Platform Protection to the 2040s ACCESS Newswire
22-Apr-2026 Assertio Provides Update on Garda Therapeutics Tender Process Businesswire
21-Apr-2026 Avenzo Therapeutics to Present Updated Results from the Phase 1 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting Businesswire
21-Apr-2026 Invenra To Feature Cancer Patient Art in Upcoming Antibody Therapy Development Project Businesswire
21-Apr-2026 Robbins LLP Urges AQST Stockholders to Contact the Firm for Information About the Class Action Against Aquestive Therapeutics, Inc. Businesswire
21-Apr-2026 ADOCIA Announces Full Year 2025 Financial Results and Provides a Corporate and Financial Update Businesswire
21-Apr-2026 FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir) Businesswire
21-Apr-2026 ADOCIA and Vester Finance sign a shareholder loan agreement, enabling ADOCIA to extend its cash runway until beginning Q2 2027 Businesswire
21-Apr-2026 Leerink Partners Initiates Medincell’s Coverage with a “Outperform” Recommendation Businesswire
21-Apr-2026 Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate ACCESS Newswire
21-Apr-2026 Uqora® Launches Cutting-Edge Urinary Health Products at Target Businesswire
21-Apr-2026 Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026 Businesswire
21-Apr-2026 Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD Businesswire
21-Apr-2026 Onco-Innovations Announces Completion of Analytical Method Development for Monomer Intermediate 1 Supporting ONC010 Program ACCESS Newswire
21-Apr-2026 Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting Businesswire
21-Apr-2026 Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting Businesswire